Back In The Saddle: Texas Biotech Opexa Re-Enters The Clinic With MS Immunotherapy
This article was originally published in The Pink Sheet Daily
Executive Summary
After a series of restructurings, a manufacturing upgrade, multiple meetings with FDA and a modest fundraising, Opexa is initiating a Phase IIb trial of its renamed T-cell immune therapy Tcelna, this time in secondary progressive MS.
You may also be interested in...
Opexa Goes Into Hold Mode, Awaiting Secondary Progressive MS Data
Biotech cuts staff by 30%, hoping for good news from Phase IIb trial due in the fourth quarter. Status of second candidate nearing the clinic is uncertain.
Opexa Pins Hope On Failed MS Vaccine’s Relapse Rate
More baseline lesions for personalized drug group cited in Phase IIb blowup
Opexa Pharmaceuticals Inc.
Opexa Pharmaceuticals was founded in February 2001 to develop therapeutic vaccines for autoimmune diseases. Based on techniques designed by co-founder Jingwu Zhang of Baylor College of Medicine, its first product is a vaccine comprised of autologous myelin-reactive T-cells that stimulate the immune response of patients with multiple sclerosis. The selectivity of the process enables greater efficacy with fewer side effects than existing therapies for MS.